Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment

PHILADELPHIA, PA – February 26, 2026 – Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

Senior Bioinformatician

We are seeking a talented and creative Senior Bioinformatician with a passion for using computational advances to prioritise and advance high-potential therapeutic antibodies and targets from Alchemab’s discovery platform through to the clinic.

Reporting into the Principal Bioinformatician, the Senior Bioinformatician will take a lead role in shaping and executing Alchemab’s computational target evaluation strategy by:

Platform Engineer

Healx is an AI-powered tech bio company that is redesigning drug discovery. With 10,000 rare diseases affecting 400 million people globally, 90% of which have no approved treatment, Healx is on a mission to pioneer the next generation of drug discovery to help rare disease patients in need. We combine data, artificial intelligence and deep pharmacology expertise to develop treatments more quickly and cheaply than traditional drug discovery.

Bioinformatician

Healx is an AI-powered tech bio company that is redesigning drug discovery. With 10,000 rare diseases affecting 400 million people globally, 90% of which have no approved treatment, Healx is on a mission to pioneer the next generation of drug discovery to help rare disease patients in need. We combine data, artificial intelligence and deep pharmacology expertise to develop treatments more quickly and cheaply than traditional drug discovery.

Senior Associate, Logistics Management (Maternity cover - 12 month FTC)

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.

Cell Therapy Scientist

At AstraZeneca's Oncology R&D department, we follow the science and pioneer new frontiers. We are a team dedicated to Oncology Cell Therapies, with an ambition to eliminate cancer as a cause of death. Our big vision unites and inspires us. With multiple indications and cutting-edge therapeutic modalities at all stages of our innovative pipeline, we keep pushing forward. Fusing groundbreaking science with the latest technology to achieve breakthroughs.

Staff Scientist

We are now seeking applications for an experienced Staff Scientist to actively contribute to exciting work. The post will be part of a dynamic group, led by Prof Jesmond Dalli, and will support the translational collaborative efforts to understand pathological mechanisms contributing to musculoskeletal diseases as part of a NIHR funded Biomedical Research Centre. The successful candidate is likely to be an energetic, focused, and productive individual with a desire to work in a congenial, dynamic, and collaborative research environment.

Senior / Research Scientist (In-vitro / Cellular Pharmacology - Peptides), London, Lausanne

About Iso

Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.

Three Strategic Leadership posts at University College London (UCL) - funded by the University College London Hospitals NHS Foundation Trust (UCLH) Strategic Research Fund (SRF)

UCL's Vice-Provost (Health) is advancing a new UCL Health Strategy that both sustains our centres of excellence and invests in strategic opportunity areas to create impact at scale with our partners. Supported by the £11.9m UCLH Strategic Research Fund (SRF)-and aligned with the NIHR UCLH Biomedical Research Centre (BRC) goals to drive innovation and clinical impact-this investment is strengthening research capacity and developing new facilities across UCLH and UCL. We are now recruiting three Strategic Leaders to drive ambitious, cross‑disciplinary programmes in:

Nxera Pharma to Receive $3 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US $3 million to Nxera pursuant to its research collaboration with Centessa.

Subscribe to